Effects of ferrofluid and phytoalexin spirobrassinin on thioflavin-T-based fluorescence in cerebrospinal fluid of the elderly and multiple sclerosis patients
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Benzothiazoles MeSH
- Chlorides cerebrospinal fluid MeSH
- Adult MeSH
- Fluorescence MeSH
- Fluorescent Dyes analysis MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Sclerosis cerebrospinal fluid diagnosis MeSH
- Aged MeSH
- Spiro Compounds cerebrospinal fluid MeSH
- Aging cerebrospinal fluid MeSH
- Thiazoles cerebrospinal fluid MeSH
- Ferric Compounds cerebrospinal fluid MeSH
- Ferrous Compounds cerebrospinal fluid MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Benzothiazoles MeSH
- Chlorides MeSH
- ferric chloride MeSH Browser
- ferrous sulfate MeSH Browser
- Fluorescent Dyes MeSH
- phytoalexin spirobrassinin MeSH Browser
- Spiro Compounds MeSH
- Thiazoles MeSH
- thioflavin T MeSH Browser
- Ferric Compounds MeSH
- Ferrous Compounds MeSH
It is well known that misfolded peptides/proteins can play a role in processes of normal ageing and in the pathogenesis of many diseases including Alzheimer's disease. Previously, we evaluated samples of cerebrospinal fluid from patients with Alzheimer's disease and multiple sclerosis by means of thioflavin-T-based fluorescence. We observed attenuated effects of magnetite nanoparticles operated via anti-aggregation actions on peptides/proteins from patients with Alzheimer's disease but not from those with multiple sclerosis when compared to age-related controls. In this study, we have evaluated the in vitro effects of anti-aggregation operating ferrofluid and phytoalexin spirobrassinin in the cerebrospinal fluid of patients with multiple sclerosis and Alzheimer's disease. We have found significant differences in native fluorescence (λ excitation = 440 nm, λ emission = 485 nm) of samples among particular groups (young controls < multiple sclerosis, Alzheimer's disease < old controls). Differences among groups were observed also in thioflavin-T-based fluorescence (young controls = multiple sclerosis < Alzheimer's disease < old controls) and the most marked change from native to thioflavin-T-based fluorescence was found in young controls (28-40 years old people). Both ferrofluid and spirobrassinin evoked drops in thioflavin-T-based fluorescence; however, ferrofluid was more efficient in old controls (54-75 years old people) and spirobrassinin in multiple sclerosis patients, both compared to young controls. The results are discussed especially in relation to aggregated peptides/proteins and liposoluble fluorescent products of lipid peroxidation. Based on the significant effect of spirobrassinin in vitro, we suggest that spirobrassinin may be of therapeutic value in multiple sclerosis.
Prague Psychiatric Centre Alzheimer Disease Centre Ustavni 91 181 03 Prague 8 Bohnice Czech Republic
See more in PubMed
Drugs Exp Clin Res. 1998;24(3):125-31 PubMed
Exp Toxicol Pathol. 2012 Jan;64(1-2):51-6 PubMed
Ann Neurol. 2001 Jul;50(1):121-7 PubMed
Brain Res Rev. 2006 Sep;52(2):316-26 PubMed
J Neurol. 2004 Mar;251(3):261-8 PubMed
Nanotechnology. 2012 Feb 10;23(5):055101 PubMed
Eur J Neurol. 2009 Jun;16(6):760-70 PubMed
Exp Parasitol. 2009 May;122(1):66-9 PubMed
J Biol Chem. 1996 Apr 26;271(17):10169-74 PubMed
Int J Clin Pharmacol Res. 1994;14(4):119-23 PubMed
Biomed Opt Express. 2010 Dec 06;2(1):71-9 PubMed
Phytochemistry. 2006 Jul;67(14):1503-9 PubMed
Anal Chem. 1994 Oct 15;66(20):3512-8 PubMed
Br J Pharmacol. 2006 Apr;147(8):873-85 PubMed
J Neurochem. 2008 Jan;104(2):457-68 PubMed
Lancet Neurol. 2005 Jan;4(1):32-41 PubMed
J Chem Biol. 2010 Mar;3(1):1-18 PubMed
Exp Gerontol. 2001 Sep;36(9):1539-50 PubMed
Anal Chem. 1999 Nov 1;71(21):4997-5002 PubMed
Mol Biosyst. 2010 Nov;6(11):2200-5 PubMed
Nat Prod Rep. 2009 Mar;26(3):382-445 PubMed
Biophys J. 2005 Jun;88(6):4200-12 PubMed
Pharm Res. 2008 Jul;25(7):1487-99 PubMed
Proteins. 2013 Jun;81(6):994-1004 PubMed
J Neurol Sci. 2012 Oct 15;321(1-2):49-53 PubMed
World J Biol Psychiatry. 2005;6(2):69-84 PubMed
Mol Biosyst. 2009 Oct;5(10):1174-9 PubMed
Alzheimers Dement. 2011 May;7(3):263-9 PubMed
Neurochem Res. 2012 Dec;37(12):2706-14 PubMed
